Preclinical studies in retinoblastoma models have also shown encouraging results: the HDAC6 inhibitor WT161 induces apoptosis and sensitizes tumor cells to cisplatin [35], whereas intravitreal belinostat effectively eradicates vitreous seeds with minimal retinal toxicity. This evidence concerns the gene HDAC6 and retinoblastoma.